Pharmaceutical composition containing prednisone as well as preparation method and application thereof

By adding sodium citrate and binder to prednisone tablets, the problem of administration difficulties and unevenness in children or small doses is solved, and a more uniform tablet distribution is achieved. Higher production efficiency.

CN118903149APending Publication Date: 2024-11-08WISDRUG INNOVATIVE DRUG RESEARCH (BEIJING) CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410971929.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing prednisone tablets are problematic in children or when they are used in small doses, and they are prone to sticking and lobeing, which leads to difficulty in administration.

Method used

Using prednisone-containing pharmaceutical compositions, including prednisone, sodium citrate and binders, prepared into small micro tablets by a combination of specific weight ratios and auxiliary materials, using water as a mixing medium, and by drying, The pellet and tableting process obtains a uniform small tablet.

Benefits of technology

The content uniformity and tablet weight difference of prednisone micro-tablets is achieved, which reduces viscosity and lobular phenomena, improves production efficiency, and is no less than that of conventional tablets in dissolution and pharmacokinetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the field of pharmaceutics, and discloses a prednisone-containing pharmaceutical composition and a preparation method and application thereof, the composition comprises prednisone, sodium citrate and an adhesive; the adhesive is selected from at least one of carbomer, hydroxypropyl methylcellulose, povidone K30 and sodium carboxymethyl cellulose. The pharmaceutical composition disclosed by the invention is not less than or even superior to imported conventional tablets in dissolution and pharmacokinetics, and is small in content uniformity and tablet weight difference, smooth in surface, less in tablet cracking / sticking condition and higher in production efficiency; the composition is very suitable for children patients, patients with dysphagia and patients with low prednisone dosage.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of pharmacy. Specifically, the present application provides a pharmaceutical composition containing prednisone and a preparation method and application thereof. Background Art

[0002] Prednisone is a type of adrenocortical hormone drug that has rapid, powerful, non-specific anti-inflammatory and anti-allergic effects and is effective for various inflammations. In the early stages of inflammation, it can inhibit capillary dilation, reduce exudation and edema, inhibit the infiltration and phagocytosis of leukocytes, and relieve inflammatory symptoms. In the late stages of inflammation, it can inhibit the proliferation of capillaries and fibroblasts, delay the formation of granulation tissue, and thus reduce inflammatory sequelae such as scars and adhesions. At the same time, prednisone can play a certain immunosuppressive role by inhibiting the phagocytosis and processing of antigens by macrophages and promoting the disintegration and destruction of lymphocytes. It can be used clinically for various acute and severe bacterial infections, severe allergic diseases, collagen diseases (lupus erythematosus, periarteritis nodosa, etc.), rheumatism, nephrotic syndrome, severe bronchial asthma, thrombocytopenic purpura, granulocytopenia, acute lymphocytic leukemia, various adrenocortical insufficiency, exfoliative dermatitis, pemphigus, neurodermatitis, eczema, etc.

[0003] The content of prednisone tablets produced by the prior art is relatively fixed and the tablet weight is relatively large, such as each tablet weighing 200-400 mg. If it is given to children or when the required amount is small, it will bring certain difficulties to the patient. If the tablets are made into small micro-tablets, it is easy to have uneven prednisone content in each tablet, and it is also easy to have sticking and / or splitting during tableting, and the weight of each tablet will also vary greatly. Summary of the invention

[0004] On the one hand, the present application provides a pharmaceutical composition containing prednisone, the pharmaceutical composition comprising prednisone, sodium citrate and a binder; wherein the binder is selected from at least one of carbomer, hydroxypropyl methylcellulose, povidone K30 and sodium carboxymethylcellulose.

[0005] Furthermore, the weight ratio of the sodium citrate to the binder is 1:0.5-5, and can be 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5 or a range formed by any two of the above values ​​and a value within the range.

[0006] In the present invention, the composition is a tablet. Preferably, the diameter of the tablet is 1-3 mm, which can be 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm or any two of the above values ​​and values ​​within the range, and the thickness is 1-3 mm, which can be 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm or any two of the above values ​​and values ​​within the range; more preferably, the weight of the tablet is 10-15 mg / tablet, which can be 10 mg / tablet, 11 mg / tablet, 12 mg / tablet, 13 mg / tablet, 14 mg / tablet, 15 mg / tablet or any two of the above values ​​and values ​​within the range.

[0007] In the present invention, the pharmaceutical composition further comprises a filler and / or a disintegrant.

[0008] In the present invention, the weight ratio of sodium citrate to filler is 1:0.2-4, and can be 1:0.2, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4 or a range formed by any two of the above values ​​and a value within the range.

[0009] In the present invention, the filler is not limited and is a filler commonly used in the art for preparing drugs, preferably at least one selected from lactose, microcrystalline cellulose, corn starch and dextrin.

[0010] In the present invention, the weight ratio of sodium citrate to disintegrant is 1:0.1-10, and can be 1:0.1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a range formed by any two of the above values ​​and a value within the range.

[0011] In the present invention, the disintegrant is not limited and is a disintegrant commonly used in the art for preparing drugs, preferably at least one selected from cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone.

[0012] In the present invention, in order to obtain tablets, other auxiliary materials such as lubricants and glidants may also be present. The lubricants and glidants are commonly used in the art for preparing drugs.

[0013] In the present invention, the content of prednisone in the composition is 0.2-65% by weight, and can be 0.2% by weight, 0.25% by weight, 0.3% by weight, 0.5% by weight, 1% by weight, 5% by weight, 10% by weight, 15% by weight, 20% by weight, 25% by weight, 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight or a range formed by any two of the above values ​​and a value within a range, preferably 10-50% by weight.

[0014] In the present invention, the weight ratio of sodium citrate to lubricant is 1:0.05-1, and can be 1:0.05, 1:0.07, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.7, 1:0.8, 1:0.9, 1:1 or the range formed by any two of the above values ​​and the value within the range. The lubricant is the lubricant commonly used in the art for preparing drugs, preferably at least one of talc, stearic acid and magnesium stearate.

[0015] In the present invention, the weight ratio of sodium citrate to glidant is 1:0.01-0.5, which can be 1:0.01, 1:0.02, 1:0.03, 1:0.04, 1:0.05, 1:0.1, 1:0.15, 1:0.2, 1:0.25, 1:0.3, 1:0.35, 1:0.4, 1:0.45, 1:0.5 or the range formed by any two of the above values ​​and the value within the range. The glidant is the glidant commonly used in the art for preparing drugs, preferably micro powder silica gel.

[0016] On the other hand, the present application provides a method for preparing the above-mentioned pharmaceutical composition, the method comprising: mixing prednisone, sodium citrate and a binder in the presence of water, wherein the binder is selected from at least one of carbomer, hypromellose, povidone K30 and sodium carboxymethylcellulose.

[0017] In the present invention, the weight ratio of each component used in the method is consistent with that in the final prepared composition.

[0018] In the present invention, in the mixed system, the content of prednisone in the dry weight is 0.2-65 weight%, and can be 0.2 weight%, 0.25 weight%, 0.3 weight%, 0.5 weight%, 1 weight%, 5 weight%, 10 weight%, 15 weight%, 20 weight%, 25 weight%, 30 weight%, 35 weight%, 40 weight%, 45 weight%, 50 weight%, 55 weight%, 60 weight%, 65 weight% or the range formed by any two of the above values ​​and the value within the range.

[0019] In the present invention, the weight ratio of the sodium citrate and the binder in the method has been described above and will not be repeated here.

[0020] In the present invention, the mixed system further includes a filler and / or a disintegrant.

[0021] In the present invention, the weight ratio of the sodium citrate to the filler in the method has been described above and will not be repeated here. The filler has also been described above and will not be repeated here.

[0022] In the present invention, the weight ratio of the sodium citrate to the disintegrant in the method has been described above and will not be repeated here. The disintegrant has also been described above and will not be repeated here.

[0023] In the present invention, the water content in the mixed product is 1-20% by weight, and can be 1% by weight, 5% by weight, 8% by weight, 10% by weight, 13% by weight, 15% by weight, 17% by weight, 20% by weight or a range formed by any two of the above values ​​and a value within the range.

[0024] Furthermore, the method further comprises: drying, granulating, mixing and tableting the mixed product to obtain tablets.

[0025] In the present invention, the drying method is not limited, and the water in the mixed system can be removed. Preferably, the drying temperature is 40-60°C, and can be 40°C, 45°C, 50°C, 55°C, 60°C or a range formed by any two of the above values ​​and a value within the range. More preferably, the water content in the dried product is less than 2% by weight.

[0026] In the present invention, the granulation is to screen the dry particles with a 40-mesh screen.

[0027] In the present invention, the total mixing is to mix the granules after granulation with the lubricant and the glidant, the mixing time is 3-5 minutes, and the mixing can be carried out in a mixer.

[0028] In the present invention, the amount and type of the lubricant and glidant have been described above and will not be repeated here.

[0029] In the present invention, the tableting is carried out in a tablet press, and the tableting pressure is 10-80N; the tablets obtained by the tableting have been described above and will not be repeated here.

[0030] On the other hand, the present application provides a pharmaceutical composition containing prednisone prepared by the above method.

[0031] In the present invention, the composition has been described above and will not be described again herein.

[0032] In another aspect, the present application provides use of a binder and sodium citrate in preparing a tablet drug containing prednisone.

[0033] Preferably, the diameter of the tablet is 1-3 mm and the thickness is 1-3 mm; more preferably, the weight of the tablet is 10-15 mg / tablet.

[0034] Another aspect of the present invention provides the use of the prednisone-containing pharmaceutical composition in preparing medicines for children, patients with dysphagia, patients receiving nasogastric feeding, and patients taking low prednisone dosages.

[0035] In the present invention, the daily dosage of prednisone is 5-60 mg, which can be 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, or a range formed by any two of the above values, or a value within the range; the age of the child is 1-144 months.

[0036] In the present invention, the patient is a patient whose disease can be treated with prednisone. The disease can be one that has been disclosed to be treatable with prednisone, such as inflammation and allergy, or can be an undisclosed disease.

[0037] The prednisone described in the present invention is prednisone acetate, chemical name: 17α, 21-dihydroxypregna-1,4-diene-3,11,20-trione 21-acetate. Molecular formula: C 23 H 28 O6, molecular weight: 400.47, structural formula:

[0038]

[0039] The above names and structural formulas can be used interchangeably to indicate the same meaning.

[0040] The micro-tablets of the present invention have better content uniformity, smaller tablet weight differences, smoother surfaces of pressed tablets, less flakes, less sticking, and higher production efficiency; and are not inferior to or even superior to imported conventional tablets in terms of dissolution and pharmacokinetics. DETAILED DESCRIPTION

[0041] raw material

[0042] Source of prednisone raw materials: Henan Lihua Pharmaceutical Co., Ltd.;

[0043] Sodium citrate source: Hunan Huari Pharmaceutical Co., Ltd.;

[0044] Carbomer Source: Lubrizol Management (Shanghai) Co., Ltd.;

[0045] Lactose source: DFE Pharma China Co., Ltd.;

[0046] Cross-linked carboxymethyl cellulose sodium source: Hubei Jiudian Hongyang Pharmaceutical Co., Ltd.;

[0047] Source of microcrystalline cellulose: Jiangsu Xidian Pharmaceutical Excipients Co., Ltd.;

[0048] Sodium carboxymethyl starch Source: Anhui Shanhe Pharmaceutical Excipients Co., Ltd.;

[0049] Corn starch source: Shandong Liujia Pharmaceutical Excipients Co., Ltd.;

[0050] Source of cross-linked povidone: Hubei Jiudian Hongyang Pharmaceutical Co., Ltd.;

[0051] Commercially available prednisone tablets: Hikma Pharmaceuticals USA lnc, specification 5 mg / tablet, tablet weight approximately 200 mg / tablet.

[0052] Example 1

[0053] The prednisone raw material is mixed with sodium citrate, carbomer, lactose and cross-linked sodium carboxymethyl cellulose to prepare a soft material (water content is 10 weight %) using a wet granulator, wherein the weight ratio of sodium citrate, carbomer, lactose and cross-linked sodium carboxymethyl cellulose is 1:1.5:1.5:0.25.

[0054] Example 2

[0055] The prednisone raw material is mixed with sodium citrate, carbomer, microcrystalline cellulose and sodium carboxymethyl starch to prepare a soft material (water content is 12 weight %) using a wet granulator, wherein the weight ratio of sodium citrate, carbomer, microcrystalline cellulose and sodium carboxymethyl starch is 1:1.5:1.5:0.25.

[0056] Example 3

[0057] The prednisone raw material is mixed with sodium citrate, carbomer, corn starch and cross-linked polyvinylpyrrolidone to prepare a soft material (water content is 8 weight%) using a wet granulator, wherein the weight ratio of sodium citrate, carbomer, corn starch and cross-linked polyvinylpyrrolidone is 1:1.5:1.5:0.25.

[0058] Example 4

[0059] The method of Example 1 is followed, except that carbomer is replaced with hypromellose.

[0060] Example 5

[0061] The method of Example 1 is followed, except that carbomer is replaced with povidone K30.

[0062] Example 6

[0063] The method of Example 1 is followed, except that carbomer is replaced with sodium carboxymethyl cellulose.

[0064] Example 7

[0065] The method of Example 1 is followed, except that the weight ratio of sodium citrate to carbomer is 1:5.

[0066] Example 8

[0067] The method of Example 1 is followed, except that the weight ratio of sodium citrate to carbomer is 1:0.5.

[0068] Comparative Example 1

[0069] The method of Example 1 was followed, except that sodium citrate was not added.

[0070] Comparative Example 2

[0071] The method of Example 1 was followed, except that carbomer was not added.

[0072] Comparative Example 3

[0073] The method of Example 1 is followed, except that sodium citrate is replaced with sodium chloride;

[0074] Comparative Example 4

[0075] The method of Example 1 is followed, except that carbomer is replaced with methylcellulose.

[0076] Test Case

[0077] Drying: The compositions obtained in the examples and comparative examples were passed through a 30-40 mesh screen to obtain wet granules, which were dried in a fluidized bed dryer at 40-60° C. to a water content of 1% by weight;

[0078] Granulation: After drying, granules are sieved with a 40-mesh screen;

[0079] Total mixing: transfer the granules after granulation to a mixer, add stearic acid and micro-powder silica gel and mix for 4 minutes, wherein the weight ratio of sodium citrate, stearic acid and micro-powder silica gel is 1:0.1:0.05;

[0080] Tablet pressing: Use a rotary microtablet press to make microtablets, flat punch, pressure 50N, and obtain microtablets with a diameter of 2.5mm, a thickness of 2.5mm, a tablet weight (theoretical amount) of 10mg, and a prednisone content (theoretical amount) of 5mg / tablet. Use an ordinary rotary tablet press to make ordinary tablets, pressure 50N, and obtain ordinary tablets with a diameter of 5.5mm, a thickness of 2mm, a tablet weight (theoretical amount) of 200mg, and a prednisone content (theoretical amount) of 5mg / tablet.

[0081] (1) In vitro dissolution

[0082] Method: The prepared microtablets and commercially available prednisone tablets were tested by the dissolution and release method (Chinese Pharmacopoeia 2020 General Rules 0931 Second Method). 900 ml of 0.1 mol / L hydrochloric acid solution was used as the dissolution medium, the speed was 50 revolutions per minute, and the operation was carried out according to the law. Samples were taken after 60 minutes (the sampling time points of the dissolution curve were 5, 10, 15, 30, 45, and 60 minutes). The dissolution results are shown in Table 1.

[0083] Table 1

[0084]

[0085]

[0086] unit:%

[0087] As can be seen from Table 1, the tablets made from the composition of the present invention have better dissolution.

[0088] (2) Pharmacokinetic parameters in beagle dogs

[0089] Method: The prednisone micro-tablets of the present invention were compared with FDA commercialized prednisone tablets 5 mg prednisone / tablet (trade name: ) was used to study the pharmacokinetic characteristics and equivalence of the drug in beagle dogs. A two-period, crossover controlled experimental design was used. After a single oral administration of 5 mg of prednisone per dog, the test preparation prednisone microtablets (T) and the commercial reference preparation prednisone tablets (R) were given to male beagle dogs. The concentration of prednisone in plasma was measured using LC-MS / MS technology. max Indicates the maximum blood drug concentration after administration; AUC 0-t AUC represents the area of ​​the blood drug concentration curve from the start of drug administration to the last point on the time axis, which is used to evaluate the degree of drug absorption; 0-∞ It represents the area enclosed by the blood drug concentration curve on the time axis from 0 to infinity, and is used to predict the degree of drug absorption.

[0090] Table 2

[0091]

[0092] As shown in Table 2, the key pharmacokinetic parameters of the microtablets prepared from the composition of the present invention for dogs are similar to those of the commercially available prednisone tablets.

[0093] (3) Content uniformity

[0094] Method: Take 10 microtablets and 10 common tablets prepared from the compositions obtained in the above examples, and test the amount of prednisone therein respectively, as follows: put them in a mortar, add an appropriate amount of anhydrous ethanol, grind, and test according to the content method (HPLC). The RSD% results of the content uniformity test are shown in Table 3.

[0095] Table 3

[0096] sample Microchip Ordinary film Example 1 3.2 3.3 Example 2 3.4 3.4 Example 3 3.9 3.8 Example 4 4.3 4.4 Example 5 4.4 4.3 Example 6 4.7 4.8 Example 7 3.3 3.4 Example 8 3.6 3.6 Comparative Example 1 6.9 6.5 Comparative Example 2 10.6 8.5 Comparative Example 3 9.8 8.6 Comparative Example 4 7.3 7.1

[0097] unit:%

[0098] As shown in Table 3, the prednisone in the tablets made from the composition of the present invention is more evenly distributed, and even in micro-tablets, the prednisone can be evenly distributed.

[0099] (4) Tablet appearance and sticking phenomenon

[0100] Method: After tableting, observe the punch and tablet. The results are shown in Table 4.

[0101] Table 4

[0102]

[0103]

[0104] It can be seen from Table 4 that the tablets made from the composition of the present invention have smooth surfaces and no sticking phenomenon.

[0105] (5) Tablet weight differences

[0106] The 2020 edition of the Pharmacopoeia of the People's Republic of China stipulates that the weight difference limit of tablets is: the weight difference limit of the average tablet weight or the labeled tablet weight below 0.30g is ±7.5%, and the weight difference limit of the average tablet weight or the labeled tablet weight is 0.30g and above is ±5%. Method: Take 20 tablets of the test sample, accurately weigh the total weight, and after obtaining the average tablet weight, accurately weigh each tablet separately, and compare the weight of each tablet with the average tablet weight (for tablets without content determination or Chinese medicine tablets with labeled tablet weight, the weight of each tablet should be compared with the labeled tablet weight). According to the above regulations, no more than 2 tablets shall exceed the weight difference limit, and no one tablet shall exceed the limit by 1 times.

[0107] Formula: Tablet weight difference = ( / tablet weight - average tablet weight / ) / average tablet weight × 100%, average tablet weight difference = sum of tablet weight differences / 20.

[0108] Table 5

[0109]

[0110]

[0111] According to Table 5, the tablet weight difference limits of the tablets made from the composition of the present invention are all within the specified range, and the tablet weight difference is lower. Even if they are prepared into micro-tablets, it can be ensured that the tablet weight difference limits are within the specified range and have a lower tablet weight difference.

[0112] It can be seen from the above results that the tablets prepared by the composition of the present invention have good content uniformity, tablet weight difference, tablet appearance and sticking condition even when made into microtablets while ensuring good dissolution and pharmacokinetic parameters.

Claims

1. A pharmaceutical composition containing prednisone, It is characterized in that The pharmaceutical composition comprises prednisone, sodium citrate and a binder; wherein the binder is selected from at least one of carbomer, hydroxypropyl methylcellulose, povidone K30 and sodium carboxymethylcellulose.

2. The pharmaceutical composition according to claim 1, in, The pharmaceutical composition further comprises a filler and / or a disintegrant; and / or, the content of prednisone in the composition is 0.2-65% by weight; And / or, the weight ratio of the sodium citrate to the binder is 1:0.5-5; And / or, the pharmaceutical composition is a tablet, the tablet has a diameter of 1-3 mm, a thickness of 1-3 mm, and a weight of 10-15 mg / tablet.

3. The pharmaceutical composition according to claim 2, in, The weight ratio of the sodium citrate, the filler and the disintegrant is 1:0.2-4:0.1-10; and / or, the filler is selected from at least one of lactose, microcrystalline cellulose, corn starch and dextrin; And / or, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone.

4. A method for preparing a pharmaceutical composition containing prednisone, It is characterized in that The method comprises: mixing prednisone, sodium citrate and a binder in the presence of water; wherein the binder is selected from at least one of carbomer, hypromellose, povidone K30 and sodium carboxymethylcellulose.

5. The method according to claim 4, in, The mixed system also includes a filler and / or a disintegrant; And / or, in the mixed system, the content of prednisone in dry weight is 0.2-65 weight %; And / or, the weight ratio of the sodium citrate to the binder is 1:0.5-5; And / or, the water content in the mixed product is 1-20% by weight.

6. The method according to claim 5, in, The weight ratio of the sodium citrate, the filler and the disintegrant is 1:0.2-4:0.1-10; and / or, the filler is selected from at least one of lactose, microcrystalline cellulose, corn starch and dextrin; And / or, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone.

7. The method according to any one of claims 4 to 6, in, The method further comprises: sequentially drying, granulating, mixing and tableting the mixed product to obtain tablets.

8. The method according to claim 7, in, The drying temperature is 40-60°C; and / or the moisture content of the dried product is less than 2% by weight; And / or, the tabletting pressure is 10-80N.

9. A pharmaceutical composition containing prednisone prepared by the method according to any one of claims 4 to 8.

10. Use of the binder according to claim 1 and sodium citrate in the preparation of tablet medicines.

Citation Information

Patent Citations

  • Cyclosporine compound eye drops and preparation method thereof

    CN107998399A

  • Prednisone acetate micro-tablet and preparation method thereof

    CN113304115A

  • Sustained release tablet and preparation method thereof

    CN115671071A

  • Prednisone enteric-coated preparation and preparation method thereof

    CN117205161A

  • Improvements in or relating to therapeutic compositions

    GB792656A